Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Universidad de Guanajuato
- Target Recruit Count
- 34
- Registration Number
- NCT04131582
- Locations
- 🇲🇽
Universidad de Guanajuato, León, Guanajuato, Mexico
A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 30
- Registration Number
- NCT04121468
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS)
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 180
- Registration Number
- NCT04116203
- Locations
- 🇨🇦
9-111 Endocrinology Department, UofA Hospital, Edmonton, Alberta, Canada
🇨🇦2-004 Li Ka Shing Centre, UofA, Edmonton, Alberta, Canada
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Dan Zandberg
- Target Recruit Count
- 72
- Registration Number
- NCT04114136
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Effect of Metformin on Chronic Pain After Thoracic Surgery in Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Xuzhou Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT04089813
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
The Antidiabetic Metformin as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients
- Conditions
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Sadat City University
- Target Recruit Count
- 80
- Registration Number
- NCT04088448
- Locations
- 🇪🇬
Faculty of Medicine, Tanta, Egypt
Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine
- Conditions
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Universidad de Guanajuato
- Target Recruit Count
- 31
- Registration Number
- NCT04088461
- Locations
- 🇲🇽
Universidad de Guanajuato, León, Guanajuato, Mexico
The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Sadat City University
- Target Recruit Count
- 120
- Registration Number
- NCT04068246
- Locations
- 🇪🇬
Faculty of Pharmacy, Shibīn Al Kawm, Menoufia, Egypt
Bioequivalence Study for Acarbose/Metformin FDC
- Conditions
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2020-04-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 24
- Registration Number
- NCT04065581
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China
Effects of Metformin on Low Back Pain
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Gwendolyn Sowa
- Target Recruit Count
- 41
- Registration Number
- NCT04055012
- Locations
- 🇺🇸
UPMC Wexford Spine Center, Wexford, Pennsylvania, United States
🇺🇸UPMC Kaufmann Medical Building, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.